Table 2.

Tumor analysis in p16^INK4A expressing T-ALL models

No.	Genotype	Time, months	Tumor	Phenotype	CD3 CD8SP	H p16/Gapdh	m p16/Gapdh
Control	p16+	ND	−	ND	ND	5.00×10−1	1.25×10−3
Control	wt	ND	−	ND	ND	ND	3.30×10−4
247	p16+TAL1+/− LMO1+/−	8.4	−	ND	ND	6.79×10−2	3.27×10−3
255	p16+TAL1+/− LMO1+/−	< 4	−	ND	ND	2.10×10−2	6.10×10−3
258	p16+TAL1+/− LMO1+/−	< 4	−	ND	ND	2.70×10−4	7.10×10−3
262	p16+TAL1+/− LMO1+/−	< 4	−	ND	ND	1.30×10−2	7.10×10−4
51	p16+TAL1+/− LMO1+/−	19.7	+	ND	ND	NA	NA
55	p16+TAL1+/− LMO1+/−	10.9	+	DP+CD8SP	High	5.80×10−4	2.39×10−1
57	p16+TAL1+/− LMO1+/−	13.8	+	ND	ND	1.12×101	2.48×10−1
67	p16+TAL1+/− LMO1+/−	5.5	+	DN2+DP+ CD4SP	Int	1.60×10−4	2.55×10−4
75	p16+TAL1+/− LMO1+/−	6.2	+	DP	Int	8.49×10−4	2.13×10−3
76	p16+TAL1+/− LMO1+/−	8.3	+	DN2	Low+int	1.28×10−1	2.70×10−3
80	p16+TAL1+/− LMO1+/−	14.7	+	DN3+DN4	Low+int	2.50×10−4	3.88×10−4
175	p16+TAL1+/− LMO1+/−	5.9	+	ND	ND	5.03×10−4	1.20×10−4
210	p16+TAL1+/− LMO1+/−	7.1	+	ND	ND	NA	NA
211	p16+TAL1+/− LMO1+/−	8.0	+	ND	ND	NA	NA
229	p16+TAL1+/− LMO1+/−	4.5	+	ND	ND	1.66×10−3	3.25×10−2
233	p16+TAL1+/− LMO1+/−	7.8	+	ND	ND	5.85×10−2	8.45×10−3
239	p16+TAL1+/− LMO1+/−	7.7	+	ND	ND	1.20×10−2	3.50×10−2
63	p16+ LMO1+/−	15.2	+	ND	ND	7.00×10−2	3.10×10−2
72	p16+ LMO1+/−	9.0	+	ND	ND	8.50×10−4	6.90×10−2
117	p16+ LMO1+/−	14.2	+	ND	ND	5.70×10−4	6.66×10−1
222	p16+ LMO1+/−	9.4	+	ND	ND	3.50×10−4	3.14×10−3
245	p16+ LMO1+/−	10.3	+	ND	ND	1.78×10−4	6.02×10−4
248	p16+ LMO1+/−	9.6	+	ND	ND	1.80×10−4	4.59×10−4
105	TAL1+/−LMO1+/−	4.7	+	ND	ND	NA	4.44×10−4
696	TAL1+/−LMO1+/−	5.0	+	ND	ND	NA	3.10×10−3
743	TAL1+/−LMO1+/−	4.3	+	ND	ND	NA	3.90×10−3
748	TAL1+/−LMO1+/−	4.6	+	ND	ND	NA	7.30×10−4

ND indicates not determined; NA, not applicable; and Int, intermediate.

^*Numbers correspond to nucleotide position in cDNA.